Activated Partial Thromboplastin Time: New Tricks for an Old Dogma

ABSTRACT

The activated partial thromboplastin time (APTT) is the most common coagulation test procedure performed in routine laboratories, apart from the prothrombin time. The test is traditionally used for identifying quantitative and qualitative abnormalities in the intrinsic and common pathways of coagulation, monitoring anticoagulant therapy with unfractionated heparin, and detecting inhibitors of blood coagulation, the most common of which is the lupus anticoagulant. Whereas short APTT values have been mostly overlooked in the past, recent evidence suggests that these might be associated with hypercoagulability. Although clinical relevance is yet to be clearly defined, hypercoagulability detected by a shortened APTT appears to be significantly associated with a major risk of venous thromboembolism independently from other variables such as blood group, the presence of inherited thrombophilia, and factor VIII levels. This novel finding suggests that this traditional, simple, and inexpensive test might have renewed utility along with traditional thrombophilic tests in the evaluation of venous thromboembolic risk. In addition, APTT waveform analysis is also providing mounting evidence of added utility, in particular for identifying sepsis and disseminated intravascular coagulation in critically ill patients (particularly where this might worsen the prognosis), for monitoring therapy in patients with inhibitors, and as a diagnostic aid to identify patients with antiphospholipid antibodies. In total, such emerging evidence suggests that the APTT is either an old dogma displaying new tricks or else might describe a new dogma for an old laboratory trick.

Activated partial thromboplastin time - clotting assay - factor V - hemophilia - therapy

REFERENCES

• 1 Lippi G, Franchini M, Guidi G C. Diagnostic approach to inherited bleeding disorders.  Clin Chem Lab Med. 2007;  45 2-12
• 2 MacFarlane R G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier.  Nature. 1964;  202 498-499
• 3 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting.  Science. 1964;  145 1310-1312
• 4 Langdell R D, Wagner R H, Brinkhous K M. Effect of anti-hemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a simple one-stage anti-hemophilic factor assay procedure.  J Lab Clin Med. 1953;  41 637-647
• 5 Proctor R R, Rapaport S I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.  Am J Clin Pathol. 1961;  36 212-219
• 6 White G C. The partial thromboplastin time: defining an era in coagulation.  J Thromb Haemost. 2003;  1 2267-2270
• 7 Clinical and Laboratory Standards Institute .Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline H21–A5, 5th ed. Wayne, PA; CLSI 2008
• 8 Manzato F, Mengoni A, Grilenzoni A, Lippi G. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.  Clin Chem Lab Med. 1998;  36 975-980
• 9 NCCLS .One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline. NCCLS document H47-A. Wayne, PA; National Committe on Clinical Laboratory Standards 1996
• 10 Lippi G, Franchini M, Montagnana M, Guidi G C. Coagulation testing in pediatric patients: the young are not just miniature adults.  Semin Thromb Hemost. 2007;  33 816-820
• 11 Favaloro E J, Lippi G, Adcock D. Preanalytical and postanalytical variables in haemostasis: the leading causes of diagnostic error?.  Semin Thromb Hemost. 2008;  34 612-634
• 12 Lippi G, Franchini M, Brazzarola P, Manzato F. Preoperative screening: the rationale of measuring APTT in risk assessment.  Haematologica. 2001;  86 328
• 13 Shetty S, Ghosh K, Mohanty D. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.  Blood Coagul Fibrinolysis. 2003;  14 493-497
• 14 Tripodi A. Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing and confirmatory studies.  Semin Thromb Hemost. 2008;  34 585-592
• 15 Favaloro E J, Soltani S, McDonald J, Grezchnik E, Easton L. Cross-laboratory audit of normal reference ranges and assessment of ABO-blood group, gender and age on detected levels of plasma coagulation factors.  Blood Coagul Fibrinolysis. 2005;  16 597-605
• 16 Tripodi A, Mannucci P M. Activated partial thromboplastin time (APTT). New indications for an old test?.  J Thromb Haemost. 2006;  4 750-751
• 17 Korte W, Clarke S, Lefkowitz J B. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.  Am J Clin Pathol. 2000;  113 123-127
• 18 Ten Boekel E, Böck M, Vrielink G J, Liem R, Hendriks H, de Kieviet W. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents.  Thromb Res. 2007;  121 361-367
• 19 McKenna R, Bachmann F, Miro-Quesada M. Thromboembolism in patients with abnormally short activated thromboplastin time.  Thromb Haemost. 1977;  38 893-899
• 20 Reddy N M, Hall S W, MacKintosh F R. Partial thromboplastin time. Prediction of adverse events and poor prognosis by low abnormal values.  Arch Intern Med. 1999;  159 2706-2710
• 21 Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci P M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.  Blood. 2004;  104 3631-3634
• 22 Hron G, Eichinger S, Weltermann A, Quehenberger P, Halbmayer W M, Kyrle P A. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.  J Thromb Haemost. 2006;  4 752-756
• 23 Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.  Br J Haematol. 2006;  134 227-232
• 24 Ten Boekel E, de Kieviet W, Bartels P C. Subjects with a shortened activated partial thromboplastin time show increased in-hospital mortality associated with elevated D-dimer, C-reactive protein and glucose levels.  Scand J Clin Lab Invest. 2003;  63 441-448
• 25 Bick R L. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations.  Semin Thromb Hemost. 1998;  24 3-18
• 26 Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1 + 2, D-dimer and FVIII:C.  Pathophysiol Haemost Thromb. 2002;  32 137-142
• 27 Mansvelt E P, Laffan M, McVey J H, Tuddenham E G. Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis.  Thromb Haemost. 1998;  80 561-565
• 28 Madi A M, Greci L S, Nawaz H, Katz D L. The activated partial thromboplastin time in early diagnosis of myocardial infarction.  Blood Coagul Fibrinolysis. 2001;  12 495-499
• 29 Downey C, Kazmi R, Toh C H. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation.  Br J Haematol. 1997;  98 68-73
• 30 Downey C, Kazmi R, Toh C H. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis.  Thromb Haemost. 1998;  80 65-69
• 31 Nesheim M, Samis J, Walker J et al.. Lipoprotein-complexed C-reactive protein and the biphasic transmittance waveform in critically ill patients.  Blood Rev. 2002;  16(Suppl 1) S15-S22
• 32 Toh C H, Samis J, Downey C et al.. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca^2 +-dependent complex of C-reactive protein with very low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation.  Blood. 2002;  100 2522-2529
• 33 Matsumoto T, Wada H, Nishioka Y et al.. Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation.  Clin Appl Thromb Hemost. 2006;  12 185-192
• 34 Bakhtiari K, Meijers J C, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation.  Crit Care Med. 2004;  32 2416-2421
• 35 Toh C H, Ticknor L O, Downey C, Giles A R, Paton R C, Wenstone R. Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.  Intensive Care Med. 2003;  29 55-61
• 36 Zakariah A N, Cozzi S M, Van Nuffelen M, Clausi C M, Pradier O, Vincent J L. Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients.  Crit Care Med. 2008;  36 1507-1512
• 37 Chopin N, Floccard B, Sobas F et al.. Activated partial thromboplastin time waveform analysis: a new tool to detect infection?.  Crit Care Med. 2006;  34 1654-1660
• 38 Dempfle C-E, Borggrefe M. The hidden sepsis marker: aPTT waveform analysis.  Thromb Haemost. 2008;  100 9-10
• 39 Hussain N, Hodson D, Marcus R, Baglin T, Luddington R. The biphasic transmittance waveform: an early marker of sepsis in patients with neutropenia.  Thromb Haemost. 2008;  100 146-148
• 40 Kasuda S, Tanaka I, Shima M et al.. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors.  Haemophilia. 2004;  10 341-346
• 41 Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.  Semin Hematol. 2004;  41 125-131